Our findings demonstrated that high levels of TGF-β mRNA in circulating EVs were significantly related to longer PFS and OS in patients with metastatic melanoma treated with first-line nivolumab or pembrolizumab monotherapy. The gene discussed is TGFB1; the disease is metastatic melanoma.